Methods and compositions involving bucindolol for the treatment of atrial fibrillation
AssigneeGenvara Biopharma, Inc.
InventorsMichael Bristow, Christopher Dufton
Life of this patent
Estimating the term…
Abstract
The current methods and compositions relate to treatment of atrial fibrillation with bucindolol in patients, including patients with heart failure, after being determined to be homozygous Arg389 in the β1 adrenergic receptor gene.
Claims19
A method for treating atrial fibrillation, the method comprising administering an effective amount of bucindolol to an atrial fibrillation or atrial flutter patient who has been identified as having at least one atrial fibrillation event within six months of the administering, (a) has been tested and found to have a left ventricle ejection fraction of greater than 0.35 and no more than 0.6;
- and (b) has been genotyped and found to be homozygous for Arg389 in the ADRB1 gene.
A method of treating atrial fibrillation, the method comprising administering an effective amount of bucindolol to a patient who:
- (a) has been diagnosed with heart failure;
- (b) has been tested and found to have a left ventricle ejection fraction of greater than 0.35 and no more than 0.6;
- (c) has been genotyped and found to be homozygous for Arg389 in the ADRB1 gene;
- and
- (d) was initially diagnosed with heart failure less than 12 years before the administering.
A method of reducing atrial fibrillation burden, the method comprising administering an effective amount of bucindolol to a patient who:
- (a) has been diagnosed with heart failure;
- (b) has been tested and found to have a left ventricle ejection fraction of at least greater than 0.35 and no more than 0.6;
- (c) has been genotyped and found to be homozygous for Arg389 in the ADRB1 gene;
- and
- (d) was initially diagnosed with atrial fibrillation less than 2 years before or after being diagnosed with heart failure.
Dependencies are inferred from the claim text.